Research supported by Starr Cancer Consortium awards is reported in the following publications. The Starr Cancer Consortium is funded by the Starr Foundation.
Harnessing nanotechnology to expand the toolbox of chemical biology.
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.
The association between tumor mutational burden and prognosis is dependent on treatment context.
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma.
The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk.